This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX

被引：0

作者：

Dimopoulos, M. A. ^{[1
]}

Oriol, A. ^{[2
]}

Nahi, H. ^{[3
,4
]}

Miguel, J. S. ^{[5
]}

Bahlis, N. J. ^{[6
]}

Rabin, N. ^{[7
]}

Orlowski, R. ^{[8
]}

Komarnicki, M. ^{[9
]}

Suzuki, K. ^{[10
]}

Plesner, T. ^{[11
,12
]}

Samoilova, O. S. ^{[13
]}

Yoon, S. S. ^{[14
]}

Yehuda, D. B. ^{[15
]}

Richardson, P. G. ^{[16
]}

Goldschmidt, H. ^{[17
,18
]}

Reece, D. ^{[19
]}

Khokhar, N. ^{[20
]}

O'Rourke, L. ^{[20
]}

Chiu, C. ^{[20
]}

Qin, X. ^{[21
]}

Guckert, M. ^{[20
]}

Ahmadi, T. ^{[20
]}

Moreau, P. ^{[22
]}

机构：

[1] Univ Athens, Athens, Greece

[2] HGTiP, Inst Catala Oncol, Barcelona, Spain

[3] Karolinska Inst, Stockholm, Sweden

[4] Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden

[5] Univ Navarra Clin, CIMA, Pamplona, Spain

[6] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[7] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England

[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[9] Poznan Univ Med Sci, Dept Hematol & Stem Cell Transplantat, Poznan, Poland

[10] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[11] Vejle Hosp, Vejle, Denmark

[12] Univ Southern Denmark, Vejle, Denmark

[13] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia

[14] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[15] Hadassah Hebrew Univ Med Ctr, Hematol Dept, Jerusalem, Israel

[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[17] Univ Hosp Heidelberg, Heidelberg, Germany

[18] German Canc Res Ctr, Heidelberg, Germany

[19] Princess Margaret Canc Ctr, CCRU, Toronto, ON, Canada

[20] Janssen Res & Dev, Spring House, PA USA

[21] Janssen Res & Dev, Horsham, PA USA

[22] Univ Hosp Hotel Dieu, Hematol, Nantes, France

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB2238

引用

页码：342 / 342

页数：1

共 50 条

[21] Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma [J].

Stewart, A. K. ;

Rajkumar, S. V. ;

Dimopoulos, M. A. ;

Mihaylov, G. G. ;

Goranova-Marinova, V. ;

Rajnics, P. ;

Suvorov, A. ;

Jakubowiak, A. J. ;

San-Miguel, J. F. ;

Zojwalla, N. ;

Moreau, P. ;

Palumbo, A. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 :20-20

[22] Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma [J].

Plesner, Torben ;

Arkenau, Hendrik-Tobias ;

Gimsing, Peter ;

Krejcik, Jakub ;

Lemech, Charlotte ;

Minnema, Monique C. ;

Lassen, Ulrik ;

Laubach, Jacob P. ;

Palumbo, Antonio ;

Lisby, Steen ;

Basse, Linda ;

Wang, Jianping ;

Sasser, A. Kate ;

Guckert, Mary E. ;

de Boer, Carla ;

Khokhar, Nushmia Z. ;

Yeh, Howard ;

Clemens, Pamela L. ;

Ahmadi, Tahamtan ;

Lokhorst, Henk M. ;

Richardson, Paul G. .

BLOOD, 2016, 128 (14) :1821-1828

[23] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial [J].

Richardson, Paul G. ;

Oriol, Albert ;

Beksac, Meral ;

Liberati, Anna Marina ;

Galli, Monica ;

Schjesvold, Fredrik ;

Lindsay, Jindriska ;

Weisel, Katja ;

White, Darrell ;

Facon, Thierry ;

Miguel, Jesus Son ;

Sunami, Kazutaka ;

O'Gorman, Peter ;

Sonneveld, Pieter ;

Robak, Pawel ;

Semochkin, Sergey ;

Schey, Steve ;

Yu, Xin ;

Doerr, Thomas ;

Bensmaine, Amine ;

Biyukov, Tsvetan ;

Peluso, Teresa ;

Zaki, Mohamed ;

Anderson, Kenneth ;

Dimopoulos, Meletios .

LANCET ONCOLOGY, 2019, 20 (06) :781-794

[24] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study [J].

Dimopoulos, Meletios ;

Quach, Hang ;

Mateos, Maria-Victoria ;

Landgren, Ola ;

Leleu, Xavier ;

Siegel, David ;

Weisel, Katja ;

Yang, Hui ;

Klippel, Zandra ;

Zahlten-Kumeli, Anita ;

Usmani, Saad Z. .

LANCET, 2020, 396 (10245) :186-197

[25] Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) [J].

Ailawadhi, Sikander ;

Paulus, Aneel ;

Alegria, Victoria R. ;

Laplant, Betsy ;

Moustafa, Muhamad Alhaj ;

Chapin, Dustin ;

Jackson, Keisha ;

Jani, Prachi ;

Ahmed, Salman ;

Edwards, Brett ;

Manna, Alak ;

Roy, Vivek ;

Sher, Taimur ;

Chanan-Khan, Asher A. .

BLOOD, 2019, 134

[26] Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk. [J].

Kaufman, Jonathan L. ;

Dimopoulos, Meletios A. ;

Leiba, Merav ;

Morton, James ;

Ho, P. Joy ;

Kim, Kihyun ;

Moreau, Philippe ;

Sutherland, Heather J. ;

Iida, Shinsuke ;

Kim, Jin Seok ;

Prince, H. Miles ;

Rocafiguera, Albert Oriol ;

Bahlis, Nizar J. ;

Chari, Ajai ;

Avet-Loiseau, Herve ;

Chiu, Christopher ;

Soong, David ;

Ukropec, Jon ;

Qi, Ming ;

San Miguel, Jesus .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[27] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study [J].

Plesner, Torben ;

Arkenau, Hendrik-Tobias ;

Gay, Francesca Marianatal ;

Minnema, Monique C. ;

Boccadoro, Mario ;

Moreau, Philippe ;

Cavenagh, James D. ;

Perrot, Aurore ;

Laubach, Jacob ;

Ahmadi, Tahamtan ;

de Boer, Carla ;

Chen, Diana ;

Chiu, Christopher ;

Schecter, Jordan ;

Richardson, Paul G. .

BLOOD, 2017, 130

[28] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study [J].

Dimopoulos, Meletios A. ;

Moreau, Philippe ;

Palumbo, Antonio ;

Joshua, Douglas ;

Pour, Ludek ;

Hajek, Roman ;

Facon, Thierry ;

Ludwig, Heinz ;

Oriol, Albert ;

Goldschmidt, Hartmut ;

Rosinol, Laura ;

Straub, Jan ;

Suvorov, Aleksandr ;

Araujo, Carla ;

Rimashevskaya, Elena ;

Pika, Tomas ;

Gaidano, Gianluca ;

Weisel, Katja ;

Goranova-Marinova, Vesselina ;

Schwarer, Anthony ;

Minuk, Leonard ;

Masszi, Tamas ;

Karamanesht, Ievgenii ;

Offidani, Massimo ;

Hungria, Vania ;

Spencer, Andrew ;

Orlowski, Robert Z. ;

Gillenwater, Heidi H. ;

Mohamed, Nehal ;

Feng, Shibao ;

Chng, Wee-Joo .

LANCET ONCOLOGY, 2016, 17 (01) :27-38

[29] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study [J].

Usmani, Saad Z. ;

Quach, Hang ;

Mateos, Maria-Victoria ;

Landgren, Ola ;

Leleu, Xavier ;

Siegel, David ;

Weisel, Katja ;

Gavriatopoulou, Maria ;

Oriol, Albert ;

Rabin, Neil ;

Nooka, Ajay ;

Qi, Ming ;

Beksac, Meral ;

Jakubowiak, Andrzej ;

Ding, Bifeng ;

Zahlten-Kumeli, Anita ;

Yusuf, Akeem ;

Dimopoulos, Meletios .

LANCET ONCOLOGY, 2022, 23 (01) :65-76

[30] Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status. [J].

Weisel, Katja C. ;

Miguel, Jesus San ;

Cook, Gordon ;

Leiba, Merav ;

Suzuki, Kenshi ;

Kumar, Shaji ;

Cavo, Michele ;

Avet-Loiseau, Herve ;

Quach, Hang ;

Hungria, Vania ;

Lentzsch, Suzanne ;

Hajek, Roman ;

Sonneveld, Pieter ;

Wu, Kaida .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →